Boehringer med cuts bleeding risk in stroke patients

Boehringer Ingelheim's new Pradaxa blood thinner lowered the risk of major bleeding in patients taking the drug to prevent another stroke or stroke-like attack, according to a new analysis of a study. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.